Literature DB >> 32530637

In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly.

Alexander K Andrianov1, Alexander Marin1, Ruixue Wang1, Ananda Chowdhury1, Pragati Agnihotri1,2,3, Abdul S Yunus1, Brian G Pierce1,2, Roy A Mariuzza1,2,3, Thomas R Fuerst1,2.   

Abstract

Two well-defined synthetic polyphosphazene immunoadjuvants, PCPP and PCEP, were studied for their ability to potentiate the immune response to the hepatitis C virus (HCV) E2 glycoprotein antigen in vivo. We report that PCEP induced significantly higher serum neutralization and HCV-specific IgG titers in mice compared to other adjuvants used in the study: PCPP, Alum, and Addavax. PCEP also shifted the response toward the desirable balanced Th1/Th2 immunity, as evaluated by the antibody isotype ratio (IgG2a/IgG1). The in vivo results were analyzed in the context of antigen-adjuvant molecular interactions in the system and in vitro immunostimulatory activity of formulations. Asymmetric flow field flow fractionation (AF4) and dynamic light scattering (DLS) analysis showed that both PCPP and PCEP spontaneously self-assemble with the E2 glycoprotein with the formation of multimeric water-soluble complexes, which demonstrates the role of polyphosphazene macromolecules as vaccine delivery vehicles. Intrinsic in vitro immunostimulatory activity of polyphosphazene adjuvants, which was assessed using a mouse macrophage cell line, revealed comparable activities of both polymers and did not provide an explanation of their in vivo performance. However, PCEP complexes with E2 displayed greater stability against agglomeration and improved in vitro immunostimulatory activity compared to those of PCPP, which is in line with superior in vivo performance of PCEP. The results emphasize the importance of often neglected antigen-polyphosphazene self-assembly mechanisms in formulations, which can provide important insights on their in vivo behavior and facilitate the establishment of a structure-activity relationship for this important class of immunoadjuvants.

Entities:  

Keywords:  complexation; hepatitis C virus; immunoadjuvants; polyphosphazenes; self-assembly; vaccine delivery; vaccines

Mesh:

Substances:

Year:  2020        PMID: 32530637      PMCID: PMC7755742          DOI: 10.1021/acs.molpharmaceut.0c00487

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  49 in total

Review 1.  Vaccine adjuvant formulations: a pharmaceutical perspective.

Authors:  Luis A Brito; Padma Malyala; Derek T O'Hagan
Journal:  Semin Immunol       Date:  2013-07-12       Impact factor: 11.130

2.  Biodegradable "Smart" Polyphosphazenes with Intrinsic Multifunctionality as Intracellular Protein Delivery Vehicles.

Authors:  Andre P Martinez; Bareera Qamar; Thomas R Fuerst; Silvia Muro; Alexander K Andrianov
Journal:  Biomacromolecules       Date:  2017-05-30       Impact factor: 6.988

3.  Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens.

Authors:  George Mutwiri; Ponn Benjamin; Henry Soita; Hugh Townsend; Richard Yost; Bryan Roberts; Alexander K Andrianov; Lorne A Babiuk
Journal:  Vaccine       Date:  2006-10-17       Impact factor: 3.641

4.  PCPP-Adjuvanted Respiratory Syncytial Virus (RSV) sF Subunit Vaccine: Self-Assembled Supramolecular Complexes Enable Enhanced Immunogenicity and Protection.

Authors:  Corinne Cayatte; Alexander Marin; Gaurav Manohar Rajani; Kirsten Schneider-Ohrum; Angie Snell Bennett; Jason D Marshall; Alexander K Andrianov
Journal:  Mol Pharm       Date:  2017-06-07       Impact factor: 4.939

Review 5.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Authors:  Christopher M Walker; Arash Grakoui
Journal:  Curr Opin Immunol       Date:  2015-08-01       Impact factor: 7.486

Review 6.  Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action.

Authors:  Royford Magiri; George Mutwiri; Heather L Wilson
Journal:  Cell Tissue Res       Date:  2018-10-08       Impact factor: 5.249

7.  Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform.

Authors:  Xia Li; Myron R Szewczuk; Cecile Malardier-Jugroot
Journal:  Drug Des Devel Ther       Date:  2016-12-15       Impact factor: 4.162

Review 8.  From empiricism to rational design: a personal perspective of the evolution of vaccine development.

Authors:  Ennio De Gregorio; Rino Rappuoli
Journal:  Nat Rev Immunol       Date:  2014-06-13       Impact factor: 53.106

9.  Self-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity.

Authors:  Alexander K Andrianov; Alexander Marin; Thomas R Fuerst
Journal:  Heliyon       Date:  2016-04-22

Review 10.  Toward precision adjuvants: optimizing science and safety.

Authors:  Etsuro Nanishi; David J Dowling; Ofer Levy
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

View more
  5 in total

1.  Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Authors:  Sarah M Valencia; Athina Zacharia; Alexander Marin; Rebecca L Matthews; Chia-Kuei Wu; Breana Myers; Chelsea Sanders; Simone Difilippantonio; Reinhard Kirnbauer; Richard B Roden; Ligia A Pinto; Robert H Shoemaker; Alexander K Andrianov; Jason D Marshall
Journal:  Hum Vaccin Immunother       Date:  2021-02-11       Impact factor: 3.452

Review 2.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

Review 3.  Asymmetric flow field-flow fractionation as a multifunctional technique for the characterization of polymeric nanocarriers.

Authors:  Federico Quattrini; Germán Berrecoso; José Crecente-Campo; María José Alonso
Journal:  Drug Deliv Transl Res       Date:  2021-01-31       Impact factor: 4.617

4.  Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate.

Authors:  Ruixue Wang; Saori Suzuki; Johnathan D Guest; Brigitte Heller; Maricar Almeda; Alexander K Andrianov; Alexander Marin; Roy A Mariuzza; Zhen-Yong Keck; Steven K H Foung; Abdul S Yunus; Brian G Pierce; Eric A Toth; Alexander Ploss; Thomas R Fuerst
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-09       Impact factor: 12.779

Review 5.  Immunopotentiating and Delivery Systems for HCV Vaccines.

Authors:  Alexander K Andrianov; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.